RAPGEF3 and diabetes mellitus: Moreover, Epac1−/− mice developed severe hyperglycemia with increased β-cell apoptosis and insulitis after type1 and immune model of diabetes using the multiple low-dose streptozotocin (MLDS; 40 mg/kg) treatment than Epac1+/+ mice.